The clinical-stage biopharma Acelyrin has appointed Bruce C. Cozadd, co-founder and CEO of Jazz Pharmaceuticals (Nasdaq:JAZZ), to its board of directors. Cozadd co-founded Jazz Pharmaceuticals in 2003. Last year, the company brought in $3 billion in revenue. Cozadd continues to serve as the company’s chairperson and CEO. Before taking the helm of Jazz Pharmaceuticals, Cozadd…
FDA approves Jazz Pharmaceuticals’ for idiopathic hypersomnia
Jazz Pharmaceuticals (NSDQ:JAZZ) has announced that its Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution has won FDA approval for treating idiopathic hypersomnia in adults. Idiopathic hypersomnia is a rare chronic disorder involving chronic excessive daytime sleepiness. Previously, the drug was FDA approved for treating cataplexy or excessive daytime sleepiness (EDS) in patients seven years…